Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 5822

Sort by

Sort Order Select

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Expect the unexpected

Didier Blaise

Blood (2021) 137 (23): 3163–3164.

https://doi.org/10.1182/blood.2021011368

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

A combination of cyclophosphamide and interleukin-2 allows CD4 + T cells converted to Tregs to control scurfy syndrome

Blood (2021) 137 (17): 2326–2336.

https://doi.org/10.1182/blood.2020009187

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood (2019) 134 (26): 2361–2368.

https://doi.org/10.1182/blood.2019001641

Published: 2019

Includes: Supplemental data

Journal Articles

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Shannon R. McCurdy, Leo Luznik

Blood (2019) 134 (21): 1802–1810.

https://doi.org/10.1182/blood.2019001323

Published: 2019

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Stable Neurocognitive Function with Improvement in Processing Speed Following Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan in Children and Adolescents with Sickle Cell Disease

Dilan A Patel, MD, Kemar V Prussien, Karina L Wilkerson, NP, MSN, Becky Armstrong, PhD, Leena Karnik, FRCPath, MRCP, Adetola A. Kassim, MDMS, Josu de la Fuente, FRCP, PhD FRCPath

Blood (2019) 134 (Supplement_1): 2277.

https://doi.org/10.1182/blood-2019-124769

Published: 2019

Journal Articles

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Ellen Cusano, Adrienne Lee, MD, Julia Hews-Girard, RN BScN MN

Blood (2019) 134 (Supplement_1): 2399.

https://doi.org/10.1182/blood-2019-129665

Published: 2019

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Immune Reconstitution in 107 Children with Sickle Cell Anemia Transplanted with Bone Marrow or Cord Blood from a Matched-Sibling Donor after Myeloablative Conditioning Regimen Including 20mg/Kg ATG

Francoise Bernaudin, MD, Azadeh Djavidi, MD, Cécile Arnaud, MD, Annie Kamdem, MD, Isabelle Hau, MD, Corinne Pondarré, MD PhD, Jean-Paul Vernant, MD, Mathieu Kuentz, MD, Nathalie Dhedin, MD, Jean-Hugues Dalle, MD PhD, Eliane Gluckman, Gerard Socie, MD PhD

Blood (2019) 134 (Supplement_1): 2253.

https://doi.org/10.1182/blood-2019-125316

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Expect the unexpected

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

A combination of cyclophosphamide and interleukin-2 allows CD4 + T cells converted to Tregs to control scurfy syndrome

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

The different flavors and splices of MCL

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Stable Neurocognitive Function with Improvement in Processing Speed Following Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan in Children and Adolescents with Sickle Cell Disease

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Immune Reconstitution in 107 Children with Sickle Cell Anemia Transplanted with Bone Marrow or Cord Blood from a Matched-Sibling Donor after Myeloablative Conditioning Regimen Including 20mg/Kg ATG

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only